Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
about
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaReview of health-related quality of life data in multiple myeloma patients treated with novel agents.A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging studyAn open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaAn open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.European perspective on multiple myeloma treatment strategies: update following recent congressesCR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.Bortezomib for the treatment of non-Hodgkin's lymphomaA Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Pain in malignant hematology.Guidelines for the diagnosis and management of multiple myeloma 2011.Bortezomib for previously untreated multiple myeloma.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Proteasome inhibitors in multiple myeloma: 10 years later.Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma.Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.Carfilzomib in multiple myeloma.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Therapy-related peripheral neuropathy in multiple myeloma patients.Current treatment landscape for relapsed and/or refractory multiple myeloma.Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.Axonal Transport Impairment in Chemotherapy-Induced Peripheral NeuropathyEvaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.Tapentadol in neuropathic pain cancer patients: a prospective open label study.
P2860
Q26862828-4FAB9D1C-541B-4CFA-8142-822C82609DB7Q28067148-B93E1F40-083F-48D0-8D9F-466FE71495B1Q28084683-F616D51C-DED6-44F8-A97F-308144034B0BQ28539605-ED04B85C-C14C-47C0-B278-2527BADF32E5Q30650394-C960EE24-B217-4CAA-89DC-1815706599B2Q33402536-3143760E-E5F1-4760-A57C-17FA49BBBB00Q33406135-DBB5112E-33CF-4D8F-A295-F9775F6D3D75Q33409681-B9C21854-7C1D-48D9-AE94-54FE5AFE5E56Q33599361-1D2304EF-009A-47D1-900F-19E01DBF677FQ34008600-9B06E8FA-4E2A-42C0-BB83-9E84BCE5E453Q34291281-9982258A-F471-4E97-B399-53ADA6783150Q35989943-86122BAD-6DAD-4063-B607-CE4B750959B3Q36084704-4A08DF61-04F2-4D05-AD59-BA23C3AC24F0Q36344699-12E30721-14EC-421A-B2DE-AB477A422DE4Q36868056-BB591EFE-898E-47B4-9B09-2164C9576818Q36965127-D900488B-1084-4EA0-9356-1853DE591463Q37659699-2A549A1B-CC45-477E-9493-1383C5A5D63BQ37662576-73D852BD-4069-4E72-A213-5F4A496180C7Q37800884-948DF544-4DEA-4B52-A812-F72B0D664C45Q37842353-E94A8AD1-9FD2-4406-BB80-A81A16B05515Q37875193-D6968D88-54CD-48D5-886C-B887966BC7CEQ37908155-11618A20-93D2-4ADE-A7A9-2C75BE6A6476Q37949201-D24ABCFC-73F9-4C1A-9201-6941D0754C17Q38014395-DF473250-0954-462C-952B-885C3BAE3281Q38095968-E92FB870-DBE2-48A1-A151-EF0458495320Q38146900-D3B2F5E9-1DE8-4477-9A7A-F6722AD0D8FEQ38209390-79922F83-FF62-4E1B-AB20-893270966869Q38244558-4B97D969-0C0A-49D8-B9C4-D37E6F02B8FEQ38246060-C083FCE0-9D45-49EC-8386-267211537348Q38268525-0E6B0D7F-C568-400A-8D27-012953592CECQ38271032-9D859475-6396-445D-9B96-649363416907Q38989789-F596A05A-4DDA-4752-BD0B-4F61378525D0Q39763096-DD14682E-1D28-43CD-B6B4-9115CEDACCA6Q40621650-1069EB16-9D07-478B-A4EB-F049E6D68E2AQ41009823-215A5A05-A132-4992-A5BC-5EC08F5C7DF5Q41279386-C9CC58BE-ABC4-4F83-B524-3AC3C55677A3Q42361415-3294B73D-4F73-4BDC-85CD-D657F4C61D1AQ42496084-52FC8DCB-6B78-4E66-A1CE-86FFE8ED02D9Q42979846-A0BF933E-1EB4-4F7D-A773-0EF4F3388D19Q47324314-88CC355B-38D9-4B8D-AC54-6CF97421AC27
P2860
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Peripheral neuropathy and new ...... and practical recommendations.
@ast
Peripheral neuropathy and new ...... and practical recommendations.
@en
type
label
Peripheral neuropathy and new ...... and practical recommendations.
@ast
Peripheral neuropathy and new ...... and practical recommendations.
@en
prefLabel
Peripheral neuropathy and new ...... and practical recommendations.
@ast
Peripheral neuropathy and new ...... and practical recommendations.
@en
P2093
P2860
P1433
P1476
Peripheral neuropathy and new ...... and practical recommendations
@en
P2093
Bilal Mohty
Jean El-Cheikh
Jean-Luc Harousseau
Mohamad Mohty
P2860
P304
P356
10.3324/HAEMATOL.2009.012674
P577
2010-02-01T00:00:00Z